Steffimycin E, a new anti-mycobacterial agent against Mycobacterium avium complex, produced by Streptomyces sp. OPMA02852

J Antibiot (Tokyo). 2020 Aug;73(8):581-584. doi: 10.1038/s41429-020-0290-9. Epub 2020 Mar 4.


The marine actinomycete strain OPMA02852, identified as the genus Streptomyces, was found to produce anti-mycobacterial compounds against Mycobacterium avium complex (MAC). One new compound, designated as steffimycin E (1), was isolated together with three known steffimycins (steffimycin (2), 10-dihydrosteffimycin (3), and 8-demethoxysteffimycin (4)) from the culture broth of this producing microorganism by solvent extraction, ODS column chromatography, and preparative HPLC. Compound 1 has a tetracyclic quinone structure with a sugar moiety. Compound 1 exhibited anti-mycobacterial activity against M. intracellulare, M. bovis BCG, and M. smegmatis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthracyclines / chemistry
  • Anthracyclines / pharmacology*
  • Antitubercular Agents / chemistry
  • Antitubercular Agents / pharmacology*
  • Cell Line, Tumor
  • HeLa Cells
  • Humans
  • Mycobacterium avium / drug effects*
  • Mycobacterium avium Complex / drug effects*
  • Mycobacterium avium-intracellulare Infection / drug therapy
  • Streptomyces / chemistry*


  • Anthracyclines
  • Antitubercular Agents
  • steffimycin